Cheilbio Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 15, 2021 at 03:41 am EST
Share
Cheilbio Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was KRW 3,409.61 million compared to KRW 4,052.71 million a year ago. Net loss was KRW 122.55 million compared to KRW 215.21 million a year ago. Basic loss per share from continuing operations was KRW 4 compared to KRW 15 a year ago. Basic loss per share was KRW 4 compared to KRW 15 a year ago.
For the nine months, sales was KRW 12,694.7 million compared to KRW 14,569.17 million a year ago. Net income was KRW 1,637.22 million compared to KRW 785.32 million a year ago. Basic earnings per share from continuing operations was KRW 58 compared to KRW 55 a year ago. Basic earnings per share was KRW 58 compared to KRW 55 a year ago.
Cheilbio Co., Ltd. is a Korea-based company engaged in the manufacturing of veterinary drugs. The Company's offerings consist of antibiotics, antimicrobials, lactobacillus, enzyme preparations, parasiticides, antiseptics, organic trace minerals, vaccines, diagnostic kits including enzyme-linked immunosorbent assay (ELISA) test kits, virus test kits and deoxyribonucleic acid (DNA) kits, as well as feed additives. The Companyâs products are used for cattle, pigs, chickens, pets and other animals. It supplies its products mainly to the domestic market.
CHEILBIO CO., LTD. 
